Rebecca C Abbott

CAR+ T-Cell Lymphoma after Cilta-cel Therapy for Relapsed or Refractory Myeloma

Simon James Harrison, Cyrille Touzeau, Nicolas Kint, Katherine Li et autres

-mutated T cells, followed by acquisition of further oncogenic genomic variants. Other potential contributors include germline genomic variation, viral infections, and previous treatment for myeloma. In the absence of direct evidence, the contribution of insertional mutagenesis to the development of T-cell lymphoma …

au, fr, be, us, de, gb (code pays fourni par la source)

Chimeric antigen receptor T cell therapy in childhood leukaemia

Stacie Shiqi Wang, Rebecca C Abbott, Maddie Gilsenan, Trevor Duke et autres

Chimeric antigen receptor (CAR) T cell therapy is a promising form of adoptive cell therapy. This process re-engineers patient-derived T cells to express a hybrid receptor targeting a selected tumour-expressed antigen. CAR T cell therapy directed against the CD19 antigen has been …

au, pg (code pays fourni par la source)

Endogenous H3.3K27M derived peptide restricted to HLA-A∗02:01 is insufficient for immune-targeting in diffuse midline glioma

Stacie Shiqi Wang, Kirti Pandey, Katherine A. Watson, Rebecca C Abbott et autres

Diffuse midline glioma (DMG) is a childhood brain tumor with an extremely poor prognosis. Chimeric antigen receptor (CAR) T cell therapy has recently demonstrated some success in DMG, but there may a need to target multiple tumor-specific targets to avoid antigen escape. …

au (code pays fourni par la source)

Human EGFRvIII chimeric antigen receptor T cells demonstrate favorable safety profile and curative responses in orthotopic glioblastoma

Rebecca C Abbott, Melinda Iliopoulos, Katherine A. Watson, Valeria Arcucci et autres

Abstract Objectives Glioblastoma is a highly aggressive and fatal brain malignancy, and effective targeted therapies are required. The combination of standard treatments including surgery, chemotherapy and radiotherapy is not curative. Chimeric antigen receptor (CAR) T cells are known to cross the blood–brain …

au, us (code pays fourni par la source)

To go or not to go? Biological logic gating engineered T cells

Rebecca C Abbott, Hannah E Hughes‐Parry, Misty Rayna Jenkins

Genetically engineered T cells have been successfully used in the treatment of hematological malignancies, greatly increasing both progression-free and overall survival in patients. However, the outcomes of patients treated with Chimeric Antigen Receptor (CAR) T cells targeting solid tumors have been disappointing. …

au, jp (code pays fourni par la source)

Novel high‐affinity EGFRvIII‐specific chimeric antigen receptor T cells effectively eliminate human glioblastoma

Rebecca C Abbott, Daniel J. Verdon, Fiona M. Gracey, Hannah E Hughes‐Parry et autres

Abstract Objectives The increasing success of Chimeric Antigen Receptor (CAR) T cell therapy in haematological malignancies is reinvigorating its application in many other cancer types and with renewed focus on its application to solid tumors. We present a novel CAR against glioblastoma, …

au (code pays fourni par la source)

Novel high‐affinity EGFRvIII‐specific chimeric antigen receptor T cells effectively eliminate human glioblastoma

Rebecca C Abbott, Daniel J. Verdon, Fiona M. Gracey, Hannah E Hughes‐Parry et autres

Clinical & Translational Immunology 2021; 10: e1317. Correction to: Clin Trans Immunol 2021; 10: e1283. https://doi.org/10.1002/cti2.1283. Published online 9 May 2021 Figure 5 originally published in this article was incorrect, as it contained a duplicated mouse image. The corrected Figure 5 and …

Finding the Keys to the CAR: Identifying Novel Target Antigens for T Cell Redirection Immunotherapies

Rebecca C Abbott, Ryan Stanley Cross, Misty Rayna Jenkins

Oncology immunotherapy has been a significant advancement in cancer treatment and involves harnessing and redirecting a patient's immune response towards their own tumour. Specific recognition and elimination of tumour cells was first proposed over a century ago with Paul Erlich's 'magic bullet' …

au (code pays fourni par la source)

CD8+ tumor‐infiltrating lymphocytes within the primary tumor of patients with synchronous de novo metastatic colorectal carcinoma do not track with survival

Rosemary Millen, Shona A. Hendry, Vignesh Narasimhan, Rebecca C Abbott et autres

Abstract Objectives Tumor‐infiltrating lymphocytes (TIL), particularly CD8+ TILs in patients with colorectal cancer (CRC), are highly prognostic in the early‐disease stages (I‐II). In metastatic disease (stage IV; mCRC), their influence is less well defined. It has presumably failed to contain tumor cells …

au (code pays fourni par la source)